I asked chatgpt what it thinks about Anavex, here is the response.
Data Transparency: There have been criticisms regarding the transparency and completeness of the data released by Anavex. Some stakeholders believe that the company has not provided enough detailed information to fully evaluate the efficacy and safety of Anavex 2-73.
Statistical Methods: Critics argue that Anavex has used various statistical methods that may make the data appear more favorable than it is. This approach has raised concerns about the robustness and reliability of the reported outcomes.
Trial Design and Delays: The design of the clinical trials and the delays in releasing full data have also been points of contention. Extended periods to provide complete trial data have led to skepticism about the results.
Regulatory Hurdles: Despite some positive signs, Anavex 2-73 faces significant regulatory hurdles. The mixed data may complicate approval processes with regulatory bodies like the FDA, which require clear and robust evidence of efficacy and safety.
Market Data 
Markets 
AI
